Acumen Stock Crashes 91%: Its Only Drug Just Failed in Alzheimer's

Acumen Pharmaceuticals (NASDAQ: ABOS) lost more than nine-tenths of its value in a single session on Friday, October 30, 2026, closing at $0.21 — down 90.8% from Thursday's $2.29 close — after the Massachusetts biotech announced that its only drug candidate, sabirnetug, had failed a Phase 2 trial in early Alzheimer's disease, and that it is ending development of the asset altogether.

What happened

Acumen reported topline results on Friday from ALTITUDE-AD, its Phase 2 study of sabirnetug in 542 people with early Alzheimer's disease. After 18 months of treatment, the drug missed the study's primary endpoint — the iADRS measure of cognition and function — at both doses tested, 35 mg/kg and 50 mg/kg, and it failed every key secondary endpoint as well. There was no meaningful difference between sabirnetug and placebo in how patients' cognition and daily function held up.

The result was not a total biological blank: amyloid plaque in the brain did decline at both doses. But clearing plaque without helping patients think or function better is not a result regulators or investors can use. The drug was generally well tolerated, although about 10% of treated participants developed ARIA-E, a form of brain swelling seen with amyloid-targeting antibodies.

The failure is total for the program. Sabirnetug — also known as ACU193, in intravenous and subcutaneous versions — was Acumen's only pipeline asset, and it held fast-track designation from the FDA. The company is terminating its development, including the trial's open-label extension.

Why the stock fell 91%

Acumen was a single-asset company: essentially its entire valuation rested on sabirnetug working. When the one asset failed, there was no second program to fall back on, and the market repriced the company in hours. The shares fell about 80% to $0.44 in pre-market trading and kept sliding into the close at $0.21, on volume of roughly 65 million shares — more than 70 times the stock's recent average of under 900,000 shares a day.

The closing market value told the story starkly: about $15.2 million, a small fraction of the $110.2 million in cash and marketable securities Acumen held at June 30, 2026. Analysts moved the same day — Citigroup downgraded the stock from Buy to Neutral and Stifel from Buy to Hold, both with $1.00 price targets. The selling also spilled into a sympathy name: ProMIS Neurosciences (NASDAQ: PMN), whose lead antibody PMN310 also targets toxic amyloid-beta oligomers, fell about 70% to $3.31 despite making no announcement of its own — any direct link between the two moves is unconfirmed.

Key facts

The close: ABOS ended Friday, October 30, 2026 at $0.21, down 90.83% from $2.29, the day's biggest percentage decline on the US market.
The trial: Phase 2 ALTITUDE-AD, 542 participants with early Alzheimer's, 18 months, doses of 35 mg/kg and 50 mg/kg.
The miss: primary iADRS endpoint and all key secondary endpoints missed; amyloid plaque fell, cognition and function did not improve.
The safety note: generally well tolerated, with ARIA-E brain swelling in about 10% of treated participants.
The balance sheet: $110.2 million in cash and marketable securities at June 30, 2026, previously expected to fund operations into early 2027.

What's next

Chief Executive Daniel O'Connell's company now says it will implement cash conservation measures and explore strategic alternatives, including its Enhanced Brain Delivery program, a technology effort aimed at getting drugs across the blood-brain barrier. One analyst cited in coverage of Friday's results argued the failure underlines that antibody sponsors may need exactly that kind of brain-shuttle technology to achieve efficacy — the amyloid mechanism's list of disappointments keeps growing. A close below $1 also puts the company's Nasdaq listing compliance on the watch list under the exchange's minimum bid-price rules. For now, Acumen ends October as a cash box with a delivery platform, a terminated drug, and a strategic review — and Friday's 91% collapse shows exactly how binary single-asset biotech stocks can be.

Sources

FAQ

Why did Acumen Pharmaceuticals stock fall 91% on Friday?

Its only drug, sabirnetug, failed the Phase 2 ALTITUDE-AD trial in early Alzheimer's disease, missing its primary and all key secondary endpoints. With no other pipeline asset, investors repriced the company from $2.29 to a $0.21 close.

What is sabirnetug?

Sabirnetug (ACU193) is an antibody designed to target toxic amyloid-beta oligomers in early Alzheimer's disease. It held FDA fast-track designation and was being developed in intravenous and subcutaneous versions — both now discontinued.

What happens to Acumen now?

The company has terminated sabirnetug development, is implementing cash conservation measures, and is reviewing strategic alternatives, including its Enhanced Brain Delivery program. It held $110.2 million in cash and marketable securities at June 30, 2026.

Did other Alzheimer's stocks fall too?

Yes. ProMIS Neurosciences, whose PMN310 also targets amyloid-beta oligomers, fell about 70% on Friday despite no announcement of its own. A direct connection between the two declines has not been confirmed.